Understanding Tresiba Prescribing Information: A Comprehensive Guide for Healthcare Providers
Tresiba is a new-generation insulin that has recently been approved by the FDA for use in the United States. Tresiba is indicated for the treatment of adults with type 1 and type 2 diabetes. As a healthcare provider, it is important to understand the prescribing information for Tresiba to ensure that patients receive safe and effective treatment. Here’s a comprehensive guide to help you better understand Tresiba prescribing information.
Overview of Tresiba
Tresiba, also known as insulin degludec, is a long-acting basal insulin that provides 24-hour glucose control. Its duration of action is longer than other long-acting insulins, which allows for flexible dosing and timing. Tresiba is available in two strengths: 100 units/mL and 200 units/mL.
Tresiba Prescribing Information
In order to prescribe Tresiba, healthcare providers should be familiar with its prescribing information. The following sections summarize the key information you need to know when prescribing Tresiba.
Indications and Usage
Tresiba is indicated for the treatment of adults with type 1 and type 2 diabetes. It should be used in combination with mealtime insulin for patients with type 1 diabetes.
Dosage and Administration
The initial dose of Tresiba should be based on the patient’s current insulin regimen and glycemic control. The dose should be adjusted based on the patient’s individual needs, with a target fasting plasma glucose level of 80-130 mg/dL.
Tresiba is available in prefilled pens and should be administered subcutaneously once daily, at any time of the day. If a dose is missed, the patient should take the missed dose as soon as possible and then continue with their regular dosing schedule. It is not recommended to use Tresiba in combination with other insulins.
Warnings and Precautions
Tresiba should not be used in patients with diabetic ketoacidosis and should be used with caution in patients with hypoglycemia unawareness. In addition, patients should be monitored for signs and symptoms of hypoglycemia and hyperglycemia.
Adverse Reactions
The most common adverse reactions associated with Tresiba are hypoglycemia, allergic reactions, injection site reactions, and pruritus (itching).
Clinical Studies
Clinical studies have shown that Tresiba provides effective glycemic control with a lower risk of hypoglycemia than other long-acting insulins. In addition, Tresiba has been shown to reduce the risk of nocturnal hypoglycemia compared to other basal insulins.
Conclusion
Tresiba is a new-generation insulin that provides 24-hour glucose control with a longer duration of action than other long-acting insulins. As a healthcare provider, it is important to understand the prescribing information for Tresiba to ensure that patients receive safe and effective treatment. With this comprehensive guide, you can confidently prescribe Tresiba and help your patients achieve their glycemic goals.
(Note: Do you have knowledge or insights to share? Unlock new opportunities and expand your reach by joining our authors team. Click Registration to join us and share your expertise with our readers.)